Churg-Strauss syndrome;Das Churg-Strauss-syndrom

Internist

Volumn 42, Issue 12, 2001, Pages 1583-1590

  Gross, W L ^a  

^a Rheumaklinik Bad Bramstedt   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ASTHMA; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DISEASE CLASSIFICATION; GERMANY; HUMAN; MORTALITY; PATHOPHYSIOLOGY; REVIEW; VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTINEOPLASTIC AGENTS; CHURG-STRAUSS SYNDROME; DIAGNOSIS, DIFFERENTIAL; EUROPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INTERFERON-ALPHA; POLYARTERITIS NODOSA; PREVALENCE; RANDOMIZED CONTROLLED TRIALS; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 0035218359     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080170009     Document Type: Review

References (46)

1. Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome
2. Churg-Strauss vasculitis and ascaris infection
3. Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases
4. Formes frustes of Churg-Strauss syndrome
5. Steroids and Churg-Strauss syndrome
6. Churg-Strauss syndrome
7. Vasculitis
8. Difficult asthma or Churg-Strauss syndrome?
9. ANCA-assoziierte Vaskulitis. Neue Konzepte und Strategien in der Therapie
10. Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression
11. Macrolid-Antibiotika induzierte Vaskulitis (Churg-Strauss syndrome)
12. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: Comparison of steroids and oral or pulse cyclophosphamide in 25 patients
13. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: Analysis of four prospective trials including 278 patients
14. Conventional immunosuppression of chronic inflammatory systemic diseases
15. Primär systemische Vaskulitiden. Teil I: Allgemeine Übersicht
16. Primär systemische Vaskulitiden. Teil II: Krankheitsbild
17. New perspectives in pulmonary angiitis - From pulmonary angiitis and granulomatosis to ANCA associated vasculitis
18. Vaskulitische periphere Neuropathie aus internistischer Sicht
19. Longterm follow up after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients
20. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients
21. Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome. Indications of plasma exchanges, meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis
22. Evidence-based treatment of systemic vasculitis
23. Nomenclature of systemic vasculitides
24. The diagnostic utility of c-ANCA in Wegener's granulomatosis
25. Treatment of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: Where do we stand?
26. Systemic vasculitis with asthma and eosinophilia: A clinical approach to the Churg-Strauss syndrome
27. Inhaled corticosteroids and Churg-Strauss syndrome: A report of five cases
28. Is it possible to offer evidence-based treatment for systemic vasculitis?
29. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis)
30. Eotaxin is required for the baseline level of tissue eosinophils
31. Churg-Strauss Syndrom
32. Apoptosis: Potential for disease therapies
33. Churg-Strauss syndrome: Serum markers of lymphocyte activation and endothelial damage
34. Improved differentiation between Churg-Strauss syndrome (CSS) and Wegener's granulomatosis (WG) by an Artificial Neural Network (ANN)
35. Circulating cytokines and soluble CD23, CD26 and CD30 in ANCA-associated vasculitides
36. Systemic vasculitis: Epidemiology, classification and environmental factors
37. Neurologic manifestations of Churg-Strauss syndrome
38. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome
39. Eosinophil active cytokines and surface analysis of eosinophils in Churg-Strauss syndrome
40. Interleukin-13's key role in asthma shown
41. Targeted disruption of stat6 DNA binding activity by an oligonucleotide decoy blocks IL-4-driven T(H)2 cell response
42. Leukotriene modifiers and Churg-Strauss syndrome
43. The eosinophilic variant of Wegener's granulomatosis